Therapeutics Therapeutic Depth Non-Alcoholic Steatohepatitis

Non-Alcoholic Steatohepatitis (NASH) CRO

Partner with a scientifically-driven CRO that has the experience and relationships in place to get your NASH & NAFLD study up and running as quickly and efficiently as possible.

Contact our NASH Team

Partner with a scientifically-driven CRO that has the experience and relationships in place to get your NASH & NAFLD study up and running as quickly and efficiently as possible.

Contact our NASH Team

NASH & NAFLD CRO Capabilities

As a therapeutically-aligned CRO, Medpace has the relevant and recent hepatology experience in indications such as non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) to successfully navigate the complexities and regulatory scrutiny often involved with these programs. Our experience, coupled with our strong relationships with KOLs and investigative sites and our in-house central lab and imaging core lab services, set you up for long term success.

NASH & NAFLD Experts

The ability to recruit patients for hepatology studies in indications such as NASH and NAFLD requires a comprehensive site feasibility assessment, a well-designed study, and established relationships with key opinion leaders and principal investigators. The in-house physicians, imaging specialists, and operational teams at Medpace can help sponsors successfully navigate the complexities and regulatory scrutiny involved with these programs. Our therapeutically-aligned teams bring a strong understanding of the key aspects of study design and patient eligibility criteria as well as the ability to manage potential challenges and logistical requirements associated with screening and enrolling these often difficult to recruit patient populations.

Two doctors having discussion about patient diagnosis

Deep Dive

Meet our NASH & Liver Disease Medical Experts

Download Now

Acute ordinary hepatitis liver biopsy under light microscopy

Integrated Central Laboratory

Through our wholly-owned laboratories in the US, Europe, China and Singapore, we have the global reach and capabilities to conduct NAFLD/NASH studies in concert with the Medpace CRO or as standalone service. With over 30 years of extensive experience, we have validated a comprehensive menu of biomarkers associated with NASH: cytokeratin-18 fragments (M30 and M65), apolipoprotein A1, apolipoprotein B, leptin, adiponectin, resistin, free fatty acids, ghrelin, hsCRP, interleukin-6, and tumor necrosis factor-alpha. Medpace Labs’ test menu also includes validated assays used in NASH fibrosis scores such as Fibrotest/ FibroMax and ELF (Enhanced Liver Fibrosis).

Medpace histology offers routine and novel pathology services for your NASH studies, including tissue processing, sectioning, general and special stains, immunohistochemistry, insitu hybridization and digital pathology services with the ability to perform select assays in a CAP-accredited, CLIA-certified laboratory.

Specialized Imaging for NAFLD/NASH Clinical Research

High-quality image acquisition and interpretation is crucial for the success of NAFLD/NASH trials. Medpace Core Labs provides comprehensive central imaging services including site assessment, qualification and training, advanced data processing and blinded assessments. In particular, Medpace Core Labs has expertise with the implementation of various MR-Based acquisition techniques including Magnetic Resonance Spectroscopy (MRS), Proton Density Fat Fraction (MRI-PDFF; magnitude and complex) and Magnetic Resonance Elastography (MRE) to support imaging endpoints for NAFLD/NASH trials using fully regulatory-compliant platforms.